Dr. Richard Carvajal, MD
Claim this profileColumbia University Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical Protoco
Studies Solid Tumors
Studies Cancer
20 reported clinical trials
60 drugs studied
About Richard Carvajal, MD
Education:
- Received MD (Doctor of Medicine) from an unspecified institution.
Experience:
- Currently serves as the Director of Experimental Therapeutics at Columbia University Medical Center (CUIMC).
- Holds the position of Director of the Melanoma Service at CUIMC's Herbert Irving Comprehensive Cancer Center Clinical Protocols, emphasizing his focus on melanoma research.
Area of expertise
1Solid Tumors
Stage IV
Stage III
Stage II
2Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Richard Carvajal, MD is currently running
CS5001
for Advanced Cancers
This trial is testing a new drug called CS5001 to see if it is safe and effective for patients with advanced blood-related and solid cancers. The drug aims to attack and stop the growth of cancer cells.
Recruiting1 award Phase 110 criteria
IDE196 Combinations
for Solid Tumors
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study. Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity. As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.
Recruiting1 award Phase 1 & 29 criteria
More about Richard Carvajal, MD
Clinical Trial Related3 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Richard Carvajal, MD has experience with
- Nivolumab
- Ipilimumab
- Binimetinib
- Crizotinib
- Ulixertinib
- Larotrectinib
Breakdown of trials Richard Carvajal, MD has run
Solid Tumors
Cancer
Melanoma
Colorectal Cancer
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Richard Carvajal, MD specialize in?
Is Richard Carvajal, MD currently recruiting for clinical trials?
Are there any treatments that Richard Carvajal, MD has studied deeply?
What is the best way to schedule an appointment with Richard Carvajal, MD?
What is the office address of Richard Carvajal, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.